HOUSTON, Oct. 18, 2018 /PRNewswire/ -- A randomized,
double-blind, placebo-controlled Phase III Clinical Trial studying
the impact of the Ubiquinol form of Coenzyme Q10 (CoQ10) on Gulf
War Illness (GWI) is being initiated at 4 Veteran's Affairs
clinical study sites across the country: Miami, Boston, Bronx, and Minneapolis. Study
investigators are actively recruiting veterans throughout the
country who were deployed to the Persian Gulf during the 1990-1991
Gulf War. The results of a prior Phase II study revealed that CoQ10
conferred benefit in physical function and symptom relief for
veterans with GWI and warranted further examination of CoQ10 in a
larger sample size. CoQ10 has been shown in many research studies
to play a role in energy production, heart health, muscle function,
and neuroimmune communication. The Phase III trial will assess the
effects of Ubiquinol, the active antioxidant form of CoQ10 from
Kaneka North America, on veterans
diagnosed with multi-symptom, chronic Gulf War Illness.
Nearly a quarter of a century after the conclusion of the Gulf
War, as many as a third of the 700,000 deployed US troops continue
to experience debilitating health problems. Veterans diagnosed with
GWI suffer from chronic symptoms that can include fatigue,
headaches, joint pain, gastrointestinal and sleep disturbances,
dizziness, respiratory disorders, and neurologic and
neuropsychological symptoms.
About CoQ10 and Ubiquinol CoQ10
There are two forms
of CoQ10 – Conventional CoQ10 and Ubiquinol CoQ10, both of which
are currently marketed in the US as dietary supplements.
These two forms differ in terms of their bioactivity within
the body. The Ubiquinol form of CoQ10 is the active, readily
available form that is used in cellular energy production
throughout the body and acts as an antioxidant, which protects the
body from oxidative stress and damage to cells. The
conventional form of CoQ10 must first be converted to the ubiquinol
form of CoQ10 in the body to contribute to the production of
cellular energy or to act as an antioxidant. However, age,
stress, health conditions and other factors can affect the body's
ability to convert conventional CoQ10 to the active form,
Ubiquinol. Cellular energy is essential to assure that energy
demanding organs like the heart, brain, liver and kidneys function
at the optimal levels. Due to the importance of Ubiquinol's role in
cellular energy production, researchers from around the world have
been studying the role Ubiquinol CoQ10 may play in mitochondrial
dysfunction, visual health and overall heart health. Now, this
study is focusing on Ubiquinol's role in energy production and
physical function.
Study Volunteers Needed
If you are a veteran deployed
to the Persian Gulf between 1990 and 1991, are experiencing
problems with fatigue, memory, mood or attention and are interested
in participating in a clinical research trial to evaluate whether
Ubiquinol CoQ10 is effective in reducing or easing the symptoms of
GWI, please contact the Principal Investigator Nancy Klimas, MD, the National Study Manager,
Devra Cohen, MPH, or the site
Investigators listed below:
Miami VA Healthcare
System, Miami, FL
|
Contact: Nancy Klimas,
MD (305) 575-3267 Nancy.Klimas@va.gov
|
Contact: Devra Cohen,
MPH (305) 575-7000 ext.3548
Devra.Cohen@va.gov
|
VA Boston Healthcare
System Jamaica Plain Campus, Jamaica Plain, MA
|
Contact: Maxine
Krengel, PhD (857) 364-6933
maxine.krengel@va.gov
|
Minneapolis VA Health
Care System, Minneapolis, MN
|
Contact: Brian Engdahl,
PhD (612) 467-3033
brian.engdahl@va.gov
|
James J. Peters VA
Medical Center, Bronx, NY
|
Contact: Julia Golier,
MD (718) 584-9000 ext. 6587
julia.golier@va.gov
|
Contact:
Ron Martin
1-281-291-3185
ronald.martin@kaneka.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/kaneka-north-america-announces-veterans-affairs-medical-centers-initiating-a-phase-iii-trial-on-the-use-of-ubiquinol-coq10-in-gulf-war-illness-gwi-300733357.html
SOURCE Kaneka North America